Use of Tears as a Biomarker in Ocular Diseases

Use of Tears as a Biomarker in Ocular Diseases


  • Muhammad Azzibaginda Ganie Students
  • Rani Himayani



Keywords: Essential Oils, Antibacterial, Antiviral, Antioxidant, Anti-inflammatory


Tears contain thousands of molecules including proteins / peptides, lipids, electrolytes, and small molecular metabolites which are secreted from the main and accessory lacrimal glands, meibomian glands, goblet cells, and eye surface epithelial cells. Tears are a source of biomarkers for eye and systemic diseases with certain advantages; in particular, non-invasive sample collection and a unique and increasingly better-defined protein composition. Biomarkers are becoming increasingly important in disease diagnosis and drug development because they have the potential to allow for more standard, objective, and precise measurement of disease and / or treatment response to therapy. The search for biomarkers is actually carried out in different body fluids, although the ideal biomarker can be found in easily accessible biological fluids, because if validated they can be searched for in a healthy population. Tears can be considered the optimal source obtained by non-invasive procedures. In recent years, scientific research has begun to focus on the study of tears for new biomarker research not only for eye diseases. In this review, presenting research on current biomarkers in tears and their relevance for clinical practice, and reports on the main results of clinical proteomics studies in eye diseases. Biomarker research in eye diseases, involving characterization of molecular and cellular components, is important to advance our understanding. about disease and developing therapy. However, this is also challenging because of the limited access to the patient's eye specimen

Keywords: Essential Oils, Antibacterial, Antiviral, Antioxidant, Anti-inflammatory


Stahl U, Willcox M, Stapleton F. Osmolality and tear film dynamics. Clin Exp Optom. 2012.

Niezgoda L, Fudalej E, Nowak A, Kopacz D. Tear film disorders as a manifestation of various diseases and conditions. Klin Oczna.

Dartt DA, Willcox MDP. Complexity of the tear film: Importance in homeostasis and dysfunction during disease. Exp Eye Res. 2013.

Aranha dos Santos V, Schmetterer L, Gröschl M, et al. In vivo tear film thickness measurement and tear film dynamics visualization using spectral domain optical coherence tomography. Opt Express. 2015. doi:10.1364/oe.23.021043

McGinnigle S, Naroo SA, Eperjesi F. Evaluation of Dry Eye. Surv Ophthalmol. 2012.

Zhou L, Beuerman RW. The power of tears: how tear proteomics research could revolutionize the clinic. Expert Rev Proteomics. 2017.

von Thun und Hohenstein-Blaul N, Funke S, Grus FH. Tears as a source of biomarkers for ocular and systemic diseases. Exp Eye Res. 2013.

Agrahari V, Mandal A, Agrahari V, et al. A comprehensive insight on ocular pharmacokinetics. Drug Deliv Transl Res. 2016.

Hanstock HG, Edwards JP, Walsh NP. Tear lactoferrin and lysozyme as clinically relevant biomarkers of mucosal immune competence. Front Immunol. 2019.

Zhou L, Zhao SZ, Koh SK, et al. In-depth analysis of the human tear proteome. J Proteomics. 2012.

Leonardi A. Allergy and allergic mediators in tears. Exp Eye Res. 2013.

Sacchetti M, Abicca I, Bruscolini A, Cavaliere C, Nebbioso M, Lambiase A. Allergic conjunctivitis: Current concepts on pathogenesis and management. J Biol Regul Homeost Agents. 2018.

Rathi VM, Murthy SI. Allergic conjunctivitis. Community eye Heal. 2017;30(99):S7-S10.

Yousefi S, Simon D, Simon HU. Eosinophil extracellular DNA traps: Molecular mechanisms and potential roles in disease. Curr Opin Immunol. 2012.

Possa SS, Leick EA, Prado CM, Martins MA, Tibério IFLC. Eosinophilic inflammation in allergic asthma. Front Pharmacol. 2013.

Shoji J, Aso H, Inada N. Clinical Usefulness of Simultaneous Measurement of the Tear Levels of CCL17, CCL24, and IL-16 for the Biomarkers of Allergic Conjunctival Disorders. Curr Eye Res. 2017.

Davidson AE, Hayes S, Hardcastle AJ, Tuft SJ. The pathogenesis of keratoconus. Eye. 2014.

Soria J, Acera A, Merayo-LLoves J, et al. Tear proteome analysis in ocular surface diseases using label-free LC-MS/MS and multiplexed-microarray biomarker validation. Sci Rep. 2017;7(1):17478.

Wong TT, Zhou L, Li J, et al. Proteomic profiling of inflammatory signaling molecules in the tears of patients on chronic glaucoma medication. Investig Ophthalmol Vis Sci. 2011.

Torok Z, Peto T, Csosz E, et al. Tear fluid proteomics multimarkers for diabetic retinopathy screening. BMC Ophthalmol. 2013.

Nishtala K, Pahuja N, Shetty R, Nuijts RMMA, Ghosh A. Tear biomarkers for keratoconus. Eye Vis. 2016.

Yamaguchi T. Inflammatory response in dry eye. Investig Ophthalmol Vis Sci. 2018.

Acera A, Vecino E, Rodríguez-Agirretxe I, et al. Changes in tear protein profile in keratoconus disease. Eye. 2011.

Pavlenko TA, Chesnokova NB, Davydova HG, Okhotsimskaia TD, Beznos O V., Grigor’ev A V. [Level of tear endothelin-1 and plasminogen in patients with glaucoma and proliferative diabetic retinopathy]. Vestn Oftalmol. 2013.

Pieragostino D, D’Alessandro M, di Ioia M, Di Ilio C, Sacchetta P, Del Boccio P. Unraveling the molecular repertoire of tears as a source of biomarkers: Beyond ocular diseases. Proteomics - Clin Appl. 2015.

Jeyabalan N, Shetty R, Ghosh A, Anandula VR, Ghosh AS, Kumaramanickavel G. Genetic and genomic perspective to understand the molecular pathogenesis of keratoconus. In: Indian Journal of Ophthalmology. ; 2013.

Chang HYP, Chodosh J. The genetics of keratoconus. Semin Ophthalmol. 2013.

Patron J, Serra-Cayuela A, Han B, Li C, Wishart DS. Assessing the performance of genome-wide association studies for predicting disease risk. PLoS One. 2019.

Ghosh A, Zhou L, Ghosh A, Shetty R, Beuerman R. Proteomic and gene expression patterns of keratoconus. In: Indian Journal of Ophthalmology. ; 2013.

Açıkalın B. Clinical findings, pathogenesis and treatment in non-infectious peripheral ulcerative keratitis. Beyoglu Eye J. 2018.

Karampatakis V, Konidaris V, Michailidou M, Gerofotis A, Daniilidis M. Peripheral corneal ulceration associated with rheumatoid arthritis. Am J Case Rep. 2013.

Hsieh JL, Shiau AL, Lee CH, et al. CD8+ T cell-induced expression of tissue inhibitor of metalloproteinses-1 exacerbated osteoarthritis. Int J Mol Sci. 2013.

Marco M, Fortin C, Fulop T. Membrane-type matrix metalloproteinases: key mediators of leukocyte function. J Leukoc Biol. 2013.

Petznick A, Madigan MC, Garrett Q, Sweeney DF, Evans MDM. Contributions of Ocular Surface Components to Matrix-Metalloproteinases (MMP)-2 and MMP-9 in Feline Tears following Corneal Epithelial Wounding. PLoS One. 2013;8(8):1-9.

Caimmi C, Crowson CS, Smith WM, Matteson EL, Makol A. Clinical correlates, outcomes, and predictors of inflammatory ocular disease associated with rheumatoid arthritis in the biologic era. J Rheumatol. 2018.

Shaharuddin B, Ahmad S, Md Latar N, Ali S, Meeson A. A Human Corneal Epithelial Cell Line Model for Limbal Stem Cell Biology and Limbal Immunobiology. Stem Cells Transl Med. 2017.

Acera A, Vecino E, Duran JA. Tear MMP-9 levels as a marker of ocular surface inflammation in conjunctivochalasis. Invest Ophthalmol Vis Sci. 2013.

Rantamäki AH, Seppänen-Laakso T, Oresic M, Jauhiainen M, Holopainen JM. Human tear fluid lipidome: From composition to function. PLoS One. 2011.

Holopainen JM, Robciuc A, Cafaro TA, et al. Pro-inflammatory cytokines and gelatinases in climatic droplet keratopathy. Investig Ophthalmol Vis Sci. 2012.

Symeonidis C, Papakonstantinou E, Galli A, et al. Matrix metalloproteinase (MMP-2, -9) and tissue inhibitor (TIMP-1, -2) activity in tear samples of pediatric type 1 diabetic patients: MMPs in tear samples from type 1 diabetes. Graefe’s Arch Clin Exp Ophthalmol. 2013.

Matsumura T, Takamura Y, Tomomatsu T, et al. Changes in matrix metalloproteinases in diabetes patients’ tears after vitrectomy and the relationship with corneal epithelial disorder. Investig Ophthalmol Vis Sci. 2015.

Suarez MF, Piqueras MC, Correa L, et al. Phospholipidomic Studies in Human Cornea From Climatic Droplet Keratopathy. J Cell Biochem. 2017.

Serra HM, Holopainen JM, Beuerman R, Kaarniranta K, Suárez MF, Urrets-Zavalía JA. Climatic droplet keratopathy: An old disease in new clothes. Acta Ophthalmol. 2015.

Fujishima H, Fukagawa K, Okada N, et al. Chemotactic responses of peripheral blood eosinophils to prostaglandin D2 in atopic keratoconjunctivitis. Ann Allergy, Asthma Immunol. 2013.

Burton MJ, Rajak SN, Hu VH, et al. Pathogenesis of Progressive Scarring Trachoma in Ethiopia and Tanzania and Its Implications for Disease Control: Two Cohort Studies. PLoS Negl Trop Dis. 2015.

Martin DL, Saboyà-Díaz MI, Abashawl A, et al. The use of serology for trachoma surveillance: current status and priorities for future investigation. PLoS Negl Trop Dis. 2020.

Pickering H, Burr SE, Derrick T, et al. Profiling and validation of individual and patterns of Chlamydia trachomatis-specific antibody responses in trachomatous trichiasis. Parasites and Vectors. 2017.

Aketa N, Yamaguchi T, Asato T, et al. Elevated Aqueous Cytokine Levels in Eyes With Ocular Surface Diseases. Am J Ophthalmol. 2017.

Marshall LL, Roach JM. Treatment of dry eye disease. Consult Pharm. 2016.

Bron AJ, Tomlinson A, Foulks GN, et al. Rethinking dry eye disease: A perspective on clinical implications. Ocul Surf. 2014.

Willcox MDP, Argüeso P, Georgiev GA, et al. TFOS DEWS II Tear Film Report. Ocul Surf. 2017.

Chiva A. Dry Eye and Clinical Disease of Tear Film – Diagnosis and Management. Eur Ophthalmic Rev. 2014;08(01):8.

D’Souza S, Tong L. Practical issues concerning tear protein assays in dry eye. Eye Vis. 2014.

Hagan S, Martin E, Enríquez-de-Salamanca A. Tear fluid biomarkers in ocular and systemic disease: Potential use for predictive, preventive and personalised medicine. EPMA J. 2016.

Versura P, Bavelloni A, Grillini M, Fresina M, Campos EC. Diagnostic performance of a tear protein panel in early dry eye. Mol Vis. 2013.

Chiva A. Electrophoresis of tear proteins as a new diagnostic tool for two high risk groups for dry eye: computer users and contact lens wearers. J Med Life. 2011.



How to Cite

Ganie, M. A., & Rani Himayani. (2021). Use of Tears as a Biomarker in Ocular Diseases: Use of Tears as a Biomarker in Ocular Diseases. Medical Profession Journal of Lampung, 11(1), 125-134.




Most read articles by the same author(s)

1 2 3 > >>